Author(s): Golmia RP, Martins AH, Scheinberg M, Golmia RP, Martins AH, Scheinberg M
Abstract Share this page
Abstract Patients with psoriasis and psoriatic arthritis respond to anti-TNF therapy, but not all patients maintain effective response, and some do not respond. In this article, we demonstrate the role of a new pathogenetic pathway to some extent TNF-independent in these patients. Anti-IL12-23 is a new and alternate mode of therapy for patients with recalcitrant response to anti-TNF.
This article was published in Rev Bras Reumatol
and referenced in Journal of Clinical & Experimental Dermatology Research